Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Indeed very unusual
I mentionned it already yesterday, problably they will PR it alsoo
At the website
5th Annual Mental health Parity Addiction Equity Act Business Roundtable in Washington DC on November 8, 2017
November 8
Anavex® Life Sciences presenting at Society for Neuroscience Nov. 11-15, 2017 in Washington DC
November 11 - November 15
When are abstracts available?
All embargoed abstracts will be made available on November 4th at 5pm Eastern Time at www.ctad-alzheimer.com. Our embargo policies are strictly enforced. All research is embargoed until the date/time that it is shared at a CTAD presentation, symposia or poster session. After the abstract presentation, you may publish/write on the abstract content.
Can I discuss CTAD abstract content before the embargo lifts?
Presentation or discussion of embargoed content at satellite meetings or press conferences before the CTAD embargo lifts is prohibited.
When are abstracts available?
All embargoed abstracts will be made available on November 4th at 5pm Eastern Time at www.ctad-alzheimer.com. Our embargo policies are strictly enforced. All research is embargoed until the date/time that it is shared at a CTAD presentation, symposia or poster session. After the abstract presentation, you may publish/write on the abstract content.
Aratana Therapeutics, Inc. (PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, plans to present at the Credit Suisse Healthcare Conference on Tuesday, November 7, 2017 at 4:30 p.m.
Wrong board
When are abstracts available?
All embargoed abstracts will be made available on November 4th at 5pm Eastern Time at www.ctad-alzheimer.com. Our embargo policies are strictly enforced. All research is embargoed until the date/time that it is shared at a CTAD presentation, symposia or poster session. After the abstract presentation, you may publish/write on the abstract content.
16:00 Opening and Introduction of Speaker Panel – Dr. Christian Marth, Chair
16:05 MOA of the listeria-based immunotherapy Axalimogene Filoslisbac (AXAL) and comparison to other immunotherapies – Dr. Sandro Pignata
16:20 AXAL clinical data in metastatic cervical cancer – Dr. Sharad Ghamande
16:35 Phase 3 clinical trial of AXAL-DUAL in combination with Nivolumab in metastatic cervical cancer – Dr. Christian Marth
Why would these experts speak for Advaxis if the science is not real ?
And they all must be shareholders, don't you think ?
Esgo perhaps ? Lol
No, read the last sentence and search fir the pre qualifying survey, it was there last week, but not now anymore
...Pharmacological Interventional Clinical Trials
________________________________________
ANAVEX 2-73 Pre-qualifying survey. Click HERE to view the flyer
I think pre qualifying ended, can't click anymore to see the flyer
When there is an event they always speak about shareholder value
Why no single reaction from management on the low pps ?
Indeed remember
Aratana and Advaxis Enter Exclusive Global Licensing Agreement
-- Collaboration Focused on Cancer Immunotherapies for Pets --
Companies to Host Conference Call Tomorrow, March 20, 2014, 8:00 a.m. Eastern Time
KANSAS CITY, Kan., and PRINCETON, N.J., March 19, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, and Advaxis, Inc. (NASDAQ: ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced a global licensing agreement for Advaxis' ADXS-cHER2 for the treatment of osteosarcoma in dogs and three additional cancer immunotherapy products for the treatment of three other types of cancer. Each of the four licensed products is based on Advaxis' platform immunotherapy technology, which Advaxis is developing for the treatment of human cancers on a global basis. Under the agreement, Aratana will have exclusive rights to develop and commercialize the licensed immunotherapies for pet health applications, and will focus initially on developing ADXS-cHER2 for osteosarcoma.
Under the agreement, Aratana made a one-time upfront payment to Advaxis of $1 million and an additional $1.5 million equity investment in Advaxis common stock and warrants. Aratana agreed to pay up to an additional $6 million in clinical and regulatory milestones for each of the four products, assuming approvals in both cats and dogs in both United States and the European Union. In addition, Aratana agreed to pay up to $28.5 million in commercial milestones. Upon regulatory approval and commercialization of the immunotherapies, Aratana agreed to pay Advaxis a tiered royalty ranging from mid-single digit to 10% on net sales.
ADXS-cHER2 was validated in an ongoing clinical study in 13 client-owned dogs with osteosarcoma, conducted by Dr. Nicola Mason at the University of Pennsylvania School of Veterinary Medicine and sponsored by Advaxis. In the study, dogs treated with ADXS-cHER2 immunotherapy after the standard of care (amputation and follow up chemotherapy), had a statistically significant prolonged overall survival benefit (p=0.032) compared with dogs that received standard of care without ADXS-cHER2. The median survival time for dogs that did not receive ADXS-cHER2 immunotherapy was eight months, whereas the median survival time for those dogs treated with ADXS-cHER2 has not yet been reached. The first four dogs treated with ADXS-cHER2 are alive, with each dog surviving over 21 months. The majority of treated dogs are tumor-free. There were no short- or long-term complications associated with the immunotherapy and only low-grade, transient toxicities were reported in the study.
Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics, stated, "We strive to accelerate the most innovative and promising new therapies for pets, and we are very encouraged by the results Advaxis has generated for ADXS-cHER2 in osteosarcoma, as well as the overall potential of their platform. Immuno-oncology is one of the most exciting advances in treating human cancers, so expanding our oncology portfolio of first in class, species specific antibodies to include Advaxis' immuno-oncology products is a natural fit. We are also particularly excited to work with the people at Advaxis and at The University of Pennsylvania, where many of our team have had long-standing relationships."
Daniel J. O'Connor, President and Chief Executive Officer of Advaxis, commented, "We admire Aratana's dedication to elevating cutting-edge drugs like ADXS-cHER2 to become potentially market-leading immunotherapies in this growing space. Given the Aratana team's combined decades of veterinary drug development experience and their leadership position in pet therapeutics, they are the ideal partner for maximizing the value of our cancer immunotherapies for pets. With upfront and potential near term multimillion dollar milestones from 16 potential approvals, this collaboration strengthens our financial ability to further advance our proprietary immunotherapies for the treatment of human cancers."
Just saw a programm on alzheimer, it was very confrontating, I really hope there will be a cure the sooner the better
Don't think with the rett syndrome trial starting
Not all have one, take a better look
It's at 3.30 pm
Dr. Scott Gottlieb, the commissioner of the Food and Drug Administration, will appear at a National Press Club Headliners Luncheon on Friday, Sept. 29 to discuss the FDA’s agenda and related issues.
Dr. Gottlieb was sworn in as the 23rd FDA commissioner on May 10th. Since taking office, he has focused on increasing efficiency and consistency in the review process, addressing the opioid crisis, growing competition as a mechanism to make pharmaceuticals more accessible, and addressing the chronic staff shortage.
I don't think there is one, can't find on the list of webcasts.
Corporate presentation has been updated today
ANAVEX 2-73 pre-qualifying online survey http://www.rettsyndrometrial.com
Indeed and there you can click on a flyer with more info about the trial
Maybe this time up after the event ?
That would be something different !
See you monday
Anthony Lombardo, interim chief executive officer, will present the company overview, focusing on the future of Lm Technologyâ„¢ and its opportunity to reach more patients while delivering GREATER VALUE
Cut loose from Biogen buyout option, Rodin preps for an early-stage shot at Alzheimer
Why ?
Nice find
On the website there is the latest abstract presented, it's number A189
Management better makes a statement to shareholders.
Tier1 company ?
Management better makes a statement to shareholders
Corporate presentation changed in august, must be very recent
IXICO, a digital technologies company serving neuroscience, expands its pilot of the Assessa PML platform including Biogen, a leading company in multiple sclerosis and expert reading institutions
Aaic 2017 brought important news ? Don't think so
You have right, I once experienced the sale with another share, once the good news was out the pps went x10
Why would Cole come if the results are bad, be realistic
Can't find them on the current list.